Abstract
Protein kinases represent an attractive target in oncology drug discovery. Most of kinase inhibitors are ATP-competitive and are called type I inhibitors. The ATP-binding pocket is highly conserved among members of the kinase family and it is difficult to find selective agents. Moreover, the ATP-competitive inhibitors must compete with high intracellular ATP levels leading to a discrepancy between IC50s measured by biochemical versus cellular assays. The non-ATP competitive inhibitors, called type II and type III inhibitors, offer the possibility to overcome these problems. These inhibitors act by inducing a conformational shift in the target enzyme such that the kinase is no longer able to function. In the DFG-out form, the phenylalanine side chain moves to a new position. This movement creates a hydrophobic pocket available for occupation by the inhibitor. Some common features are present in these inhibitors. They contain a heterocyclic system that forms one or two hydrogen bonds with the kinase hinge residue. They also contain a hydrophobic moiety that occupies the pocket formed by the shift of phenylalanine from the DFG motif. Moreover, all the inhibitors bear a hydrogen bond donor-acceptor pair, usually urea or amide, that links the hinge-binding portion to the hydrophobic moiety and interacts with the allosteric site. Examples of non ATP-competitive inhibitors are available for various kinases. In this review small molecules capable of inducing the DFG-out conformation are reported, especially focusing on structural feature, SAR and biological properties.
Keywords: Allosteric, antitumor activity, inhibition, kinase, non-ATP competitive, SAR
Current Medicinal Chemistry
Title: Non-ATP Competitive Protein Kinase Inhibitors
Volume: 17 Issue: 25
Author(s): L. Garuti, M. Roberti and G. Bottegoni
Affiliation:
Keywords: Allosteric, antitumor activity, inhibition, kinase, non-ATP competitive, SAR
Abstract: Protein kinases represent an attractive target in oncology drug discovery. Most of kinase inhibitors are ATP-competitive and are called type I inhibitors. The ATP-binding pocket is highly conserved among members of the kinase family and it is difficult to find selective agents. Moreover, the ATP-competitive inhibitors must compete with high intracellular ATP levels leading to a discrepancy between IC50s measured by biochemical versus cellular assays. The non-ATP competitive inhibitors, called type II and type III inhibitors, offer the possibility to overcome these problems. These inhibitors act by inducing a conformational shift in the target enzyme such that the kinase is no longer able to function. In the DFG-out form, the phenylalanine side chain moves to a new position. This movement creates a hydrophobic pocket available for occupation by the inhibitor. Some common features are present in these inhibitors. They contain a heterocyclic system that forms one or two hydrogen bonds with the kinase hinge residue. They also contain a hydrophobic moiety that occupies the pocket formed by the shift of phenylalanine from the DFG motif. Moreover, all the inhibitors bear a hydrogen bond donor-acceptor pair, usually urea or amide, that links the hinge-binding portion to the hydrophobic moiety and interacts with the allosteric site. Examples of non ATP-competitive inhibitors are available for various kinases. In this review small molecules capable of inducing the DFG-out conformation are reported, especially focusing on structural feature, SAR and biological properties.
Export Options
About this article
Cite this article as:
Garuti L., Roberti M. and Bottegoni G., Non-ATP Competitive Protein Kinase Inhibitors, Current Medicinal Chemistry 2010; 17 (25) . https://dx.doi.org/10.2174/092986710791859333
DOI https://dx.doi.org/10.2174/092986710791859333 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Compounds as Heme Oxygenase-1 Inducers to Reduce the Deleterious Consequences Following SARS-CoV-2 Infection
Current Chemical Biology Conservation of Hydrophobicity within Viral Envelope Glycoproteins Reveals a Putative Hepatitis C Virus Fusion Peptide
Protein & Peptide Letters A Nanotechnology-based Strategy to Increase the Efficiency of Cancer Diagnosis and Therapy: Folate-conjugated Gold Nanoparticles
Current Medicinal Chemistry Sequence Analysis, Structure Prediction of Receptor Proteins and <i>In Silico</i> Study of Potential Inhibitors for Management of Life Threatening COVID-19
Letters in Drug Design & Discovery Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design Mass Spectrometry-Based Metabolic Profiling
Current Metabolomics Chitosan Oligomer and Zinc Oxide Nanoparticles for Treating Wastewaters: US20190134086 Patent Evaluation
Recent Patents on Biotechnology Computational Approaches for the Discovery of Cysteine Protease Inhibitors Against Malaria and SARS
Current Computer-Aided Drug Design Preface
Current Medicinal Chemistry Biotechnological Production of Taxol and Related Taxoids: Current State and Prospects
Anti-Cancer Agents in Medicinal Chemistry New Insights into Chemistry and Anti-Infective Potential of Triazole Scaffold
Current Medicinal Chemistry Loneliness as Risk Factor for Alzheimer´s disease
Current Aging Science Some Recent Approaches of Biologically Active Substituted Pyridazine and Phthalazine Drugs
Current Medicinal Chemistry Targeting the Hedgehog Signaling Pathway with Small Molecules
Anti-Cancer Agents in Medicinal Chemistry Naphthyridines with Antiviral Activity - A Review
Medicinal Chemistry Impact of COVID-19 on Mental Dimension of Health: A Sensitive Issue to be Addressed at the Earliest
Current Psychiatry Research and Reviews Formulation and Optimization of Topical Solid Lipid Nanoparticles based Gel of Dapsone Using Design of Experiment
Pharmaceutical Nanotechnology The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy
Current Medicinal Chemistry Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Interpretable SMILES-based QSAR Model of Inhibitory Activity of Sirtuins 1 and 2
Combinatorial Chemistry & High Throughput Screening